Stocks · News reference
J.P. Morgan analyst John Stansel maintained a Hold rating on Centene Corporation while increasing the price target from $67 to $75.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Oscar Health is diversifying revenue streams beyond ACA insurance through Lucie, an enhanced direct enrollment platform targeting a $650+ billion marketplace, and CHOICE, which capitalizes on growing ICHRA adoption. While the company has gained 116.1% year-to-date, its stock trades at a premium valuation (P/E of 14.17 vs. industry average of 9.02) with consensus estimates showing projected revenue and earnings decreases for 2026-2027.
UBS analyst A.J. Rice maintained a neutral rating on Centene Corporation while raising the price target from $70 to $78.
Cantor Fitzgerald has maintained an Overweight rating on Centene Corporation and increased its price target for the company's stock to $79.